



Market Announcement

1 December 2020

Noxopharm Limited (ASX: NOX) – Trading Halt

Description

The securities of Noxopharm Limited ('NOX') will be placed in trading halt at the request of NOX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 3 December 2020 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)



ASX Announcement | 1 December 2020
Noxopharm Limited (ASX:NOX)

Noxopharm Limited – Trading Halt

Ms Melissa Kostopoulos
Adviser
Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4 Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By Email: melissa.kostopoulos@asx.com.au
By Email: tradinghaltsmelbourne@asx.com.au

Dear Melissa,

NOXOPHARM LIMITED – TRADING HALT

The Company requests a trading halt effective immediately pending the release of an announcement relating to a capital raising program (“Capital Raising”).

The trading halt is requested until the earlier of the release of an announcement relating to the Company’s Capital Raising or prior to the opening of trading on Thursday 3rd December 2020.

The Company is not aware of any reason why the trading halt should not be granted.

Thank you for your assistance. If you have any questions please contact the Company Secretary, David Franks on 0414 899 897.

Yours faithfully,

David Franks
Company Secretary
Noxopharm Limited



Graham Kelly, Noxopharm CEO and Managing Director, has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking the development of septic shock.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries

Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.